Analysts' Top 5 Price Targets of November 4, 2025
Reading Time: 3 minutes
Terns Pharmaceuticals [US8808811074] Jefferies maintains Buy rating and raises the price target from $28 to $35 (136% upside potential) The reason for the price target increase was new data published as part of the ASH Abstracts. These are the 6-month results of the Phase 1 study CARDINAL for the drug TERN-701, which is being developed for the treatment of chronic myeloid leukemia (CML). Jefferies views these early study results as promising. They see a solid foundation for further development of TERN-701 – both as a first-line therapy...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
